$13.30
+7.5%ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
CLPT • NASDAQ
| ClearPoint Neuro, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||
37M | 31.4M | 24M | 20.6M | 16.3M | 12.8M | 11.2M | 7.4M | 7.4M | 5.7M | 4.6M | 3.6M | 3.9M | 5.1M | 3.8M | 2.7M | |
GROSS PROFIT | ||||||||||||||||
(14.3M) | (12.3M) | (10.3M) | (7M) | (5.2M) | (3.7M) | (3.9M) | (2.4M) | (2.9M) | (2.6M) | (2M) | (1.9M) | (1.4M) | (555.7K) | (656.4K) | (16.3K) | |
22.7M | 19.1M | 13.6M | 13.5M | 11.1M | 9.1M | 7.3M | 4.9M | 4.5M | 3.1M | 2.6M | 1.7M | 2.5M | 4.5M | 3.2M | 2.7M | |
OPERATING INCOME | ||||||||||||||||
(46.9M) | (38.9M) | (36.1M) | (29.9M) | (24.5M) | (15.3M) | (11.9M) | (10.2M) | (10.8M) | (10.6M) | (10.3M) | (11.3M) | (10M) | (7.6M) | (9.1M) | (10.4M) | |
(33M) | (26.5M) | (24.4M) | (19M) | (15.2M) | (10.7M) | (9.1M) | (7.9M) | (8M) | (8M) | (8.4M) | (8M) | (7.1M) | (6M) | (4.8M) | (4.7M) | |
(13.9M) | (12.4M) | (11.7M) | (10.9M) | (9.3M) | (4.7M) | (2.8M) | (2.3M) | (2.8M) | (2.6M) | (2M) | (3.3M) | (2.9M) | (1.6M) | (4.3M) | (5.7M) | |
-24.2M | -19.7M | -22.4M | -16.3M | -13.4M | -6.2M | -4.6M | -5.2M | -6.3M | -7.5M | -9M | -5.3M | -7.5M | -3.1M | -5.9M | -9.5M | |
PRE-TAX INCOME | ||||||||||||||||
(2.4M) | (0.0) | (0.0) | (81K) | (973K) | (1.4M) | (955K) | (980.4K) | (872.9K) | (1.1M) | (1.3M) | (1M) | (499.8K) | (2.6M) | (2.5M) | (1.6M) | |
-1.2M | 872K | 386K | -81K | -973K | -1.4M | -955K | -980.4K | -872.9K | -1.1M | -1.2M | -1M | -475.3K | -2.6M | -2.5M | -1.6M | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (364.0) | (16.7K) | (0.0) | (0.0) | (0.0) | (0.0) | (2.8K) | (0.0) | (0.0) | |
-1.3M | 832K | 357K | -103K | -1M | -562K | -946K | -915.7K | -831.5K | -581.2K | 524.9K | 795.9K | 388.5K | -2.6M | -2.4M | 61.1K | |
-25.5M | -18.9M | -22.1M | -16.4M | -14.4M | -6.8M | -5.5M | -6.2M | -7.2M | -8.1M | -8.4M | -4.5M | -7.1M | -5.7M | -8.3M | -9.5M | |
NET INCOME | ||||||||||||||||
(55K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (2.2M) | (0.0) | (0.0) | |
-25.5M | -18.9M | -22.1M | -16.4M | -14.4M | -6.8M | -5.5M | -6.2M | -7.2M | -8.1M | -8.4M | -4.5M | -7.1M | -5.7M | -8.3M | -9.5M |
CLPT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 21, 2026 | May 20, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 13, 2026 | May 13, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 10, 2026 | April 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 17, 2026 | March 17, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 17, 2026 | December 31, 2025 | 2025 | |
8-K/A 8-K/A 2025 (Amended) N/A | February 05, 2026 | November 20, 2025 | 2025 | |
S-3 S-3 N/A | January 14, 2026 | January 14, 2026 | ||
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 05, 2026 | January 05, 2026 | 2026 |
Continue your CLPT research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.